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Abstract 
Background: Allergen Immunotherapy is a promising treatment of allergy. Seven patients with rhinoconjunctivitis 
to grass allergen were treated with intralymphatic immunotherapy (ILIT) to explore whether this treatment could be 
performed. Effect of treatment was assessed as change in symptom medication score, response in skin prick test and 
nasal allergen provocation. ILIT deposits allergen in an inguinal lymph node to elicit a strong immune stimulus. This 
allowed us to monitor appearance of allergen specific plasmablasts 7 days after allergen injection.
Findings: In an open trial of seven patients with a history of symptomatic allergic rhinoconjunctivitis due to grass 
pollen, three injections of allergen into inguinal lymph nodes were performed with monthly intervals. Allergen injec-
tions induced grass allergen specific plasmablasts expressing other isotypes than IgE after 7 days, induced a trend 
toward improvement in symptom and medication score and rhinoconjunctivitis-related quality of life during the grass 
pollen season 2013 and significantly raised the threshold in nasal allergen challenge and titrated skin prick testing. 
Mild side-effects were recorded after 3 of the 21 of injections (14 %).
Conclusions: This pilot study shows that ILIT may induce allergen specific plasmablasts, and confirms an effect on 
provocation of mast cells in skin and nasal mucosa during the ensuing winter.
Keywords: Allergen immunotherapy, Intralymphatic immunotherapy, Grass pollen allergy, Allergen specific 
plasmablasts, Symptom medication score
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Background
Allergic rhinoconjunctivitis is a growing global health 
problem and causes a significant clinical and socio-
economic burden in Western countries [1]. English 
high school graduates with allergic airway disease finish 
school with a lower grade than non-allergic high school 
graduates [2]. The only disease modifying treatment 
available is allergen immunotherapy (AIT), which tar-
gets the underlying immunological mechanisms. Sub-
cutaneous immunotherapy (SCIT) is a time demanding 
and costly treatment, requiring 30–80 injections over 
3–5  years. Sublingual immunotherapy requires long-
term treatment where compliance may be an issue [3].
The efficacy of intralymphatic immunotherapy (ILIT), 
where allergen is injected into inguinal lymph nodes, 
has been assessed in recent studies [4–6]. Two trials 
published reported clinical effect comparable to that of 
SCIT [4, 5]. A recent placebo-controlled randomized trial 
with injections every 2 weeks had a large number of side 
effects and did not show clinical effect [6]. We would like 
to contribute to this discussion with our open pilot study. 
We involved a radiologist to ascertain that we injected 
allergen into lymph nodes as this may be paramount to 
the success of this treatment [7] and adhered to the pro-
tocol of former, successful trials in which injections of 
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AIT is thought to induce a protective IgG response [9]. 
Circulating plasmablasts are required for induction of 
new immunoglobulin, and have previously been identi-
fied in circulation 7 days after a tetanus vaccination [10]. 
We reasoned that we would be able to identify allergen 
specific plasma blasts in circulation 7 days after injection 
of allergen in an inguinal lymph node.
The aim of this pilot project was to establish ILIT in 
our clinic and to evaluate clinical and paraclinical out-
come measures.
Methods
Seven patients (age range 23–41, 4 women) with a his-
tory of symptomatic rhino-conjunctivitis due to grass 
pollen allergy recruited as open control group for a SCIT 
study [9] accepted the option of ILIT as alternative to 
SCIT. Diagnosis was confirmed by positive skin prick test 
(SPT, wheal >3 mm) and positive nasal allergen challenge 
(NAC). The regional scientific ethics committee approved 
the study (Number 1-10-72-132-13, 13-06-2013). It was 
monitored by the local GCP unit and was conducted in 
accordance with good clinical practice guidelines. All 
participants gave written informed consent before the 
study was initiated. This study is registered in Eudra-CT 
with number 2012-005227-33, 22-03-2013.
Allergen extract (0.1  ml Alutard Phleum pratense, 
10.000 SQU/ml, ALK-abelló, Hoersholm, Denmark) was 
injected into a superficial inguinal lymph node guided by 
ultrasound (GE Logiq S8). Injections were given on the 
same side and preferably into the same lymph node with 
23–36 days interval. The last injection was given 2 weeks 
after initiation of the 2013 grass pollen season. Partici-
pants recorded daily combined symptom and medication 
score (SMS) and weekly rhninitis related quality of life 
using the RQLQ(s) questionnaire during the grass pollen 
seasons of 2012 and 2013. Patients 2 and 4 did not sub-
mit SMS data. Daily pollen counts were obtained from 
the Danish Meteorological Institute (www.dmi.dk) and 
summarized as AUC during the whole season. Titrated 
SPT and NAC were performed during autumn following 
the pollen seasons of 2012 and 2013 as described previ-
ously [9]. Titrated baseline SPT data are not available for 
patient 6.
We adapted the Euroflow approach to identify plas-
mablasts [11], and confirmed their specificity by stain-
ing with fluorochrome-conjugated grass allergen and 
antibody to IgE to distinguish between IgE and non-IgE 
producing plasmablasts. Euroflow antibodies are an 
established panel used for B-LCL detection. The specific-
ity of Grass and IgE antibodies was confirmed with blood 
basophils from grass-sensitised patients. We calculated 
the number of IgE+, and IgE- CD19+CD20-CD27bright-
CD38bright plasmablasts specific for grass per ml blood 
using Trucount® beads, at baseline before the first injec-
tion and 7 days after each allergen injection.
SMS and Rhino-conjunctivitis quality of life question-
naires (RQLQ(s)) were evaluated by calculating area 
under the curve (AUC) of the reported data during the 
pollen seasons. Data were compared using Wilcoxon 
matched pairs signed-rank test. Individual data and 
medians are displayed.
Grass pollen component specific IgE and IgG4 levels 
of eight available components were measured on the 
ISAC-chip (Thermo Fisher Scientific, Uppsala, Swe-
den) before starting ILIT and during autumn following 
the first grass pollen season after the treatment. For the 
comparisons in this study the values for the eight com-
ponents were summed for each patient, timepoint and 
isotype.
Basophil sensitivity was determined five times (before 
treatment, after every treatment injection and after one 
allergen season) with Aquagen Grass allergen (ALK Hør-
sholm, Denmark) as described previously [9].
Results
Seven patients received three injections. One partici-
pant registered local swelling at the injection site, a sec-
ond patient registered local itching and a third decrease 
by 19  % in PEF, that quickly normalized after inhala-
tion of beta2-agonist. All these side effects occurred 
after the first ILIT injection. We compared combined 
symptom–medication scores (SMS) from the previous 
years´ seasons to the grass pollen season 2013 (Fig. 1a). 
Total grass pollen counts and length of the pollen sea-
son were comparable between the seasons of 2012 (2390 
grains) and 2013 (2216 grains). SMS were reduced after 
ILIT (p = 0.0625). RQLQ scores from season 2013 were 
comparable to that of previous seasons (p = 0.26). Tol-
erance to grass pollen increased significantly in NAC 
(p  =  0.031) and titrated SPT (p  <  0.006) performed 
before ILIT and after the ensuing grass pollen season 
(Fig. 1b, c).
In ILIT allergen is injected directly into the lymph node 
to strongly stimulate the adaptive immune system at a 
known time and date. We hypothesized that we would 
be able to detect allergen-specific non-IgE plasma blasts 
7 days after allergen injection into a lymph node as has 
been shown for tetanus vaccination [10]. The concen-
tration of circulating plasmablasts increased after ILIT. 
Normalised to day 7 (100 %), there were 41 % on day 6, 
102 % on day 8 and 88 % plasmablasts on day 9 after an 
intralymphatic allergen injection (not shown). Seven days 
after the first injection, we found more than a doubling 
of allergen specific, non-IgE plasmablasts in all patients 
(Fig. 1d). After the second injection we found a >fivefold 
increase in the allergen specific, non-IgE plasmablast 
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concentration (p =  0.016). After the third injection, we 
found more than a doubling of allergen specific, non-
IgE plasmablast concentration compared with the base-
line visit (p  =  0.016). The increase in allergen-specific, 
IgE+ plasmablasts did not reach significance at any visit 
(Fig. 1e), but maximal increase 7 days after any injection 
in total grass specific plasmablasts, non-IgE plasmablasts 
and IgE+ plasmablasts was significant (p = 0.0078). The 
frequency of birch-specific IgE− plasmablasts in the sin-
gle patient double sensitised with birch and grass did not 
change.
Summed IgE specific for eight grass allergens did not 
increase during treatment; the median at baseline was 
9.3 ISU/L (IQR 0.73–69.63), and 57.91 ISU (IQR 21.53–
76.66) after treatment and one season (p  =  0.24). The 
corresponding IgG4 measurements were 0.03  ISU/L 
(IQR 0.0–0.96) at baseline, and 0 ISU/L (IQR 0–0) after 
treatment and one season (p = 0.9).
Basophil sensitivity was attenuated during subcutane-
ous immunotherapy, and predicted treatment success [9]. 
We assessed basophil sensitivity as a biomarker of ILIT at 
five visits; at baseline, and preceding every allergen injec-
tion and after one grass pollen season. Neither basophil 
reactivity nor sensitivity changed significantly as a result 
of ILIT (data not shown).
Discussion
Self-reported symptom–medication scores of five 
patients as well as paraclinical measures of seven patients 
suggest that ILIT may relieve symptoms and reduce med-
ication use, and increase the threshold at which patients 
respond to NAC and SPT. The three patients with the 
most severe symptoms reported a decrease in SMS.
In this study, a radiologist and a pulmonary consultant 
trained to biopsy lymph nodes identified lymph nodes 
and injected allergen to ensure a correct deposition of 
allergen in inguinal lymph nodes. We recorded 3 side 
effects amongst 21 allergen injections, only one of them 
a mild grade 1 systemic reaction. This was similar to 
the side effects reported from previous studies [4, 5]. A 
higher rate of side effects may be explained by allergen 
injected proximal to, rather than into lymph nodes. Injec-
tion frequency may be crucial for the clinical efficacy [7]. 
We adhered to allergen injection at 4-week intervals used 
where ILIT was successful [4, 5, 8].
Allergen specific IgE+ and IgE− plasmablasts were 
detected in patient blood. The frequency of allergen specific 
IgE− plasmablasts increased significantly 7 days after injec-
tion of allergen into an inguinal lymph node. In contrast 
to previous reports [12] we determined absolute concen-
trations between 1 and 100 plasmablasts/ml. This is a first 
report characterising plasmablasts arising from AIT that 
will have to be refined and confirmed by other methods.
Fig. 1 Impact of ILIT on Symptom medication score (SMS) (a), nasal 
allergen challenge (NAC) (b), skin prick test diameter >3 mm (c) and 
allergen specific non-IgE (d) and IgE (e) plasma cell numbers 1 week 
after each allergen injection (Vn + 7d). Nonparametric tests were 
used to evaluate treatment effect
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In contrast to SCIT, we found no significant changes in 
grass pollen component specific IgE or IgG4 levels [13] 
or in basophil sensitivity [9]. The post ILIT samples may 
have been taken too soon after the grass pollen season. 
Alternatively, the mechanism of ILIT may be different—
and possibly similar to that induced by peptide immu-
notherapy [14]. In both peptide allergen immunotherapy 
and ILIT, the allergic effector cell (mast cell and basophil 
granulocyte) adaptation described for SCIT [15, 16] may 
be circumvented, and the adaptive immune response tar-
geted directly.
We report an open trial of ILIT that may have a 
large placebo effect. The primary outcome parameter, 
improvement of SMS, was not significantly reduced. 
However, allergen specific plasmablasts were induced by 
treatment, and objective measures of clinical improve-
ment, NAC and SPT, improved. We are now exploring 
the effect of ILIT on grass pollen induced rhino-con-
junctivitis in a double blind, placebo controlled trial 
(EUDRACT 2012-005227-33).
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